Table 2 Sample composition across experimental platforms and cohorts

From: A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities

Assay Type

BrM Discovery Cohort

BrM Validation Cohort

Primary

GBM

Independent Cohort

WES

Newly generated

78

    

Public data

82

    

Bulk Transcriptomic

Newly generated

107

207

3

20

 

Public data

249

449

79

  

Bulk Proteomics (mass spectrometry)

Newly generated

107

 

3

20

 

Public data

11

 

11

  

Targeted Metabolomics

Newly generated

74

    

Public data

12

 

12

  

snRNA-seq

Newly generated

16

    

10x Genomics Visium

Newly generated

12

 

4

  

PhenoCycler-Fusion 2.0

Newly generated

20

3

   

DSP

Public data

    

41 BrMs, 54 primary tumors

IHC

Newly generated

12

    

mIF

Newly generated

6

    

Public data

12

    

Patient-derived Organoids (PDOs)

Newly generated

14

4

  

20 BrM-PDOs

  1. Comprehensive summary of sample numbers for each experimental assay, broken down by newly collected vs. publicly available data and by cohort (Discovery vs. Validation).
Back to article page